Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Conditions
Interventions
Ozanimod
Locations
766
United States
Holland Center for Family Health
Peoria, Arizona, United States
Local Institution - 202
Scottsdale, Arizona, United States
Local Institution - 026
North Little Rock, Arkansas, United States
Local Institution - 284
Camarillo, California, United States
Sharp Chula Vista Medical Center
Chula Vista, California, United States
Local Institution - 039
Garden Grove, California, United States
Start Date
August 24, 2018
Primary Completion Date
October 31, 2024
Completion Date
October 31, 2024
Last Updated
September 17, 2025
NCT05421455
NCT07245394
NCT07089420
NCT05698745
NCT06953791
NCT04263831
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions